Atypical adenomatous hyperplasia of the prostate

A critical review

David Grignon, W. A. Sakr

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: The aim of this report is to review the literature concerning atypical adenomatous hyperplasia (AAH) with specific regard to evidence in support of or refuting its role as a precursor lesion for prostatic adenocarcinoma. Methods: The available literature was collected and critically reviewed. In addition, recently reported (abstract) but as yet unpublished data were included. Particular attention was focused on biological studies. Results: There is considerable morphologic evidence suggesting that AAH is associated with low-grade (Gleason patterns 1 and 2) adenocarcinoma arising in the transition zone. Only limited biologic studies have been performed. There is weak and limited data to indicate that AAH has a proliferation rate higher than hyperplasia but lower than adenocarcinoma. AAH is diploid, as are most examples of low-grade adenocarcinoma. A few markers (blood group antigens, peanut agglutinin) show similar paterns of expression in AAH and adenocarcinoma while others (carbohydrate D-galactose-N-acetyl-D-galactosamine) do not. Recent cytogenetic analyses have detected abnormalities of chromosome 8 in a very small proportion (4-6%) of cases of AAH studied. Conclusions: Presently, the only strong evidence linking AAH to adenocarcinoma is morphologic. The few biologic and molecular/cytogenetic studies performed have not provided convincing evidence to support or refute this possibility. Additional studies are required. Finally, in comparative studies of AAH with adenocarcinoma, the latter should include low-grade transition zone tumors.

Original languageEnglish (US)
Pages (from-to)206-211
Number of pages6
JournalEuropean Urology
Volume30
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Hyperplasia
Prostate
Adenocarcinoma
Peanut Agglutinin
Acetylgalactosamine
Chromosomes, Human, Pair 8
Cytogenetic Analysis
Blood Group Antigens
Diploidy
Galactose
Cytogenetics
Carbohydrates
Neoplasms

Keywords

  • Adenocarcinoma
  • Adenosis
  • Atypical adenomatous hyperplasia
  • Premalignant lesion
  • Prostate
  • Transition zone

ASJC Scopus subject areas

  • Urology

Cite this

Atypical adenomatous hyperplasia of the prostate : A critical review. / Grignon, David; Sakr, W. A.

In: European Urology, Vol. 30, No. 2, 1996, p. 206-211.

Research output: Contribution to journalArticle

@article{449d526c5dff45d9b1772808a557f176,
title = "Atypical adenomatous hyperplasia of the prostate: A critical review",
abstract = "Aims: The aim of this report is to review the literature concerning atypical adenomatous hyperplasia (AAH) with specific regard to evidence in support of or refuting its role as a precursor lesion for prostatic adenocarcinoma. Methods: The available literature was collected and critically reviewed. In addition, recently reported (abstract) but as yet unpublished data were included. Particular attention was focused on biological studies. Results: There is considerable morphologic evidence suggesting that AAH is associated with low-grade (Gleason patterns 1 and 2) adenocarcinoma arising in the transition zone. Only limited biologic studies have been performed. There is weak and limited data to indicate that AAH has a proliferation rate higher than hyperplasia but lower than adenocarcinoma. AAH is diploid, as are most examples of low-grade adenocarcinoma. A few markers (blood group antigens, peanut agglutinin) show similar paterns of expression in AAH and adenocarcinoma while others (carbohydrate D-galactose-N-acetyl-D-galactosamine) do not. Recent cytogenetic analyses have detected abnormalities of chromosome 8 in a very small proportion (4-6{\%}) of cases of AAH studied. Conclusions: Presently, the only strong evidence linking AAH to adenocarcinoma is morphologic. The few biologic and molecular/cytogenetic studies performed have not provided convincing evidence to support or refute this possibility. Additional studies are required. Finally, in comparative studies of AAH with adenocarcinoma, the latter should include low-grade transition zone tumors.",
keywords = "Adenocarcinoma, Adenosis, Atypical adenomatous hyperplasia, Premalignant lesion, Prostate, Transition zone",
author = "David Grignon and Sakr, {W. A.}",
year = "1996",
language = "English (US)",
volume = "30",
pages = "206--211",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Atypical adenomatous hyperplasia of the prostate

T2 - A critical review

AU - Grignon, David

AU - Sakr, W. A.

PY - 1996

Y1 - 1996

N2 - Aims: The aim of this report is to review the literature concerning atypical adenomatous hyperplasia (AAH) with specific regard to evidence in support of or refuting its role as a precursor lesion for prostatic adenocarcinoma. Methods: The available literature was collected and critically reviewed. In addition, recently reported (abstract) but as yet unpublished data were included. Particular attention was focused on biological studies. Results: There is considerable morphologic evidence suggesting that AAH is associated with low-grade (Gleason patterns 1 and 2) adenocarcinoma arising in the transition zone. Only limited biologic studies have been performed. There is weak and limited data to indicate that AAH has a proliferation rate higher than hyperplasia but lower than adenocarcinoma. AAH is diploid, as are most examples of low-grade adenocarcinoma. A few markers (blood group antigens, peanut agglutinin) show similar paterns of expression in AAH and adenocarcinoma while others (carbohydrate D-galactose-N-acetyl-D-galactosamine) do not. Recent cytogenetic analyses have detected abnormalities of chromosome 8 in a very small proportion (4-6%) of cases of AAH studied. Conclusions: Presently, the only strong evidence linking AAH to adenocarcinoma is morphologic. The few biologic and molecular/cytogenetic studies performed have not provided convincing evidence to support or refute this possibility. Additional studies are required. Finally, in comparative studies of AAH with adenocarcinoma, the latter should include low-grade transition zone tumors.

AB - Aims: The aim of this report is to review the literature concerning atypical adenomatous hyperplasia (AAH) with specific regard to evidence in support of or refuting its role as a precursor lesion for prostatic adenocarcinoma. Methods: The available literature was collected and critically reviewed. In addition, recently reported (abstract) but as yet unpublished data were included. Particular attention was focused on biological studies. Results: There is considerable morphologic evidence suggesting that AAH is associated with low-grade (Gleason patterns 1 and 2) adenocarcinoma arising in the transition zone. Only limited biologic studies have been performed. There is weak and limited data to indicate that AAH has a proliferation rate higher than hyperplasia but lower than adenocarcinoma. AAH is diploid, as are most examples of low-grade adenocarcinoma. A few markers (blood group antigens, peanut agglutinin) show similar paterns of expression in AAH and adenocarcinoma while others (carbohydrate D-galactose-N-acetyl-D-galactosamine) do not. Recent cytogenetic analyses have detected abnormalities of chromosome 8 in a very small proportion (4-6%) of cases of AAH studied. Conclusions: Presently, the only strong evidence linking AAH to adenocarcinoma is morphologic. The few biologic and molecular/cytogenetic studies performed have not provided convincing evidence to support or refute this possibility. Additional studies are required. Finally, in comparative studies of AAH with adenocarcinoma, the latter should include low-grade transition zone tumors.

KW - Adenocarcinoma

KW - Adenosis

KW - Atypical adenomatous hyperplasia

KW - Premalignant lesion

KW - Prostate

KW - Transition zone

UR - http://www.scopus.com/inward/record.url?scp=0029818843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818843&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 206

EP - 211

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -